NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $32.72 0.00 (0.00%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$32.68 -0.04 (-0.11%) As of 03/14/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Harmony Biosciences Stock (NASDAQ:HRMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$32.06▼$33.0550-Day Range$32.18▼$40.4652-Week Range$28.14▼$41.61Volume489,131 shsAverage Volume631,629 shsMarket Capitalization$1.88 billionP/E Ratio15.51Dividend YieldN/APrice Target$53.11Consensus RatingBuy Company OverviewHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More… Remove Ads Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 86th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHarmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth27.98% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 15.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 15.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.68.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.99% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 4.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.99% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 4.00%, indicating that investor sentiment is decreasing. News and Social Media3.9 / 5News Sentiment1.00 News SentimentHarmony Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Harmony Biosciences this week, compared to 6 articles on an average week.Search Interest7 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows6 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,831,679.00 in company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMYMarch 11, 2025 | prnewswire.comHarmony Biosciences to Present at Upcoming Global Healthcare ConferencesMarch 10, 2025 | msn.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…March 15, 2025 | Investors Alley (Ad)Harmony Biosciences to Participate in Upcoming Investor ConferencesMarch 4, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMYMarch 3, 2025 | prnewswire.comHarmony Biosciences price target lowered to $70 from $75 at H.C. WainwrightFebruary 27, 2025 | markets.businessinsider.comIs Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now?February 26, 2025 | insidermonkey.comHarmony Biosciences price target raised to $33 from $31 at BofAFebruary 26, 2025 | markets.businessinsider.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $34.41 on January 1st, 2025. Since then, HRMY shares have decreased by 4.9% and is now trading at $32.72. View the best growth stocks for 2025 here. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released its quarterly earnings data on Tuesday, February, 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. The firm's quarterly revenue was up 19.5% on a year-over-year basis. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional investors include Valor Management LLC (11.60%), FMR LLC (9.35%), Vanguard Group Inc. (8.30%) and Pacer Advisors Inc. (4.00%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, John C Jacobs, Sandip Kapadia, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings2/25/2025Today3/14/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$53.11 High Stock Price Target$70.00 Low Stock Price Target$40.00 Potential Upside/Downside+62.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.51 Trailing P/E Ratio15.51 Forward P/E Ratio13.47 P/E Growth0.47Net Income$128.85 million Net Margins17.98% Pretax Margin25.71% Return on Equity23.16% Return on Assets14.24% Debt Debt-to-Equity Ratio0.28 Current Ratio3.24 Quick Ratio3.20 Sales & Book Value Annual Sales$714.73 million Price / Sales2.63 Cash Flow$2.45 per share Price / Cash Flow13.38 Book Value$7.97 per share Price / Book4.11Miscellaneous Outstanding Shares57,346,000Free Float39,465,000Market Cap$1.88 billion OptionableOptionable Beta0.82 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:HRMY) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.